CSPC Pharmaceutical Group Limited (1093.HK)

5.770 -0.090 (-1.54%) At close: 04:08PM HKT

CSPC Pharmaceutical Group Limited

No. 226 Huanghe Street
Shijiazhuang 050035
China
86 31 1870 37015
https://www.cspc.com.hk

Sector(s): Healthcare
Industry: Drug Manufacturers - General
Full-time employees: 23,500

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Dongchen Cai	Executive Chairman	21.26M	N/A	1954
Mr. Cuilong Zhang	Vice-Chairman & CEO	11.56M	N/A	1969
Mr. Chunlei Li	Executive Director & Chief Scientist	8.3M	N/A	1976
Mr. Kin Man Chak	Executive Director	5.71M	N/A	1966
Mr. Huaiyu Wang	Executive Director	6.91M	N/A	1963
Mr. Zhenguo Wang	Executive Director	5.98M	N/A	1970
Dr. Qingxi Wang Ph.D.	Executive Director	4.93M	N/A	1966
Dr. Hao Jiang	Executive Director	5.48M	N/A	1983
Mr. Tai On Lo CPA	Company Secretary	N/A	N/A	1954

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.

Description

CSPC Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People's Republic of China, other Asian regions, the Americas, Europe, and internationally. The company operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. It provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson's disease; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent leucopenia and infection induced by chemotherapy; and Keaili for breast cancer. The company also offers Shuluoke, Nuomoling, Weihong, and Xinweihong for various infections; Xuanning for hypertension; Encun to prevent atherosclerotic thrombosis events; Qixiao to treat upper respiratory tract infection; Linmeixin and Shuanglexin for diabetes; Gubang and Gubangjia to treat osteoporosis in postmenopausal women; and Gaoshunsong for arthritis, osteoarthritis, ankylosing spondylitis, frozen shoulder, bursuitis, tenosynovitis, acute gout, dysmenorrhea, toothache and postoperative pain, low back pain, sprain, strain, and other soft tissue injuries. In addition, it provides Debixin for various ulcer; Qimaite for acute and chronic pains; antibiotics, vitamin C, and caffeine APIs; functional food and glucose products; and healthcare services. The company has a strategic partnership with Pfizer Inc. to launch a local brand of the COVID-19 oral therapeutic treatment Nirmatrelvir/Ritonavir in China. The company was formerly known as China Pharmaceutical Group Limited and changed its name to CSPC Pharmaceutical Group Limited in March 2013. CSPC Pharmaceutical Group Limited was incorporated in 1992 and is headquartered in Shijiazhuang, the People's Republic of China.

Corporate governance

CSPC Pharmaceutical Group Limited’s ISS governance QualityScore as of 1 April 2024 is 8. The pillar scores are Audit: 9; Board: 5; Shareholder rights: 4; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.